<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239992</url>
  </required_header>
  <id_info>
    <org_study_id>KP-Niacin-2010</org_study_id>
    <secondary_id>2010-019954-42</secondary_id>
    <nct_id>NCT01239992</nct_id>
  </id_info>
  <brief_title>Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia</brief_title>
  <official_title>Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial
      lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and
      postprandial biomarkers of endothelial dysfunction and inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    negative endpoint study resulting in withdrawal of study drug
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Area Under the Plasma Triglyceride Curve Over 8 Hours Following a Standardized Oral Fat Tolerance Test</measure>
    <time_frame>baseline and 12 weeks after treatment</time_frame>
    <description>Percent change of incremental AUC at 12 weeks compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>baseline and 12 weeks after treatment</time_frame>
    <description>Percent change of HDL-cholesterol at 12 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Triglycerides</measure>
    <time_frame>baseline and 12 weeks after treatment</time_frame>
    <description>Percent change of fasting triglycerides at 12 weeks compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>baseline and 12 weeks after treatment</time_frame>
    <description>Percent change of LDL-cholesterol at 12 weeks compared to baseline</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hyperlipoproteinemia</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Niacin/ Laropiprant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin/ Laropiprant</intervention_name>
    <description>1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
    <arm_group_label>Niacin/ Laropiprant</arm_group_label>
    <other_name>Tredaptive</other_name>
    <other_name>EU/1/08/459/001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects or postmenopausal female subjects aged between 19-70 years

          -  High risk patients (PROCAM risk ≥20%) on a stable statin-therapy, but at least
             simvastatin 20 mg/d

          -  HDL-cholesterol ≤50 mg/dl and /or triglycerides 150-400 mg/dl and/or LDL-cholesterol
             70 - 150 mg/dl

          -  Lipoprotein (a) &lt; 30 mg/dl

          -  Patients may have normal glucose metabolism (normal HOMA), be insulin resistant
             (abnormal HOMA), have impaired fasting glucose or impaired glucose tolerance but not
             diabetes mellitus.

          -  Without niacin therapy for at least 6 months

          -  Dosage of any concomitant medication has been stable for at least 3 weeks

          -  If female, postmenopausal (absence of menstruation for at least 12 months or absence
             of menstruation &gt; 6 months with FSH &gt; 40 ng/ml respectively oestrogen &lt; 20 pg/ml)

        Exclusion Criteria:

          -  Subjects with additional causes for hyperlipoproteinemia

          -  Diabetes mellitus or antidiabetic medication

          -  Subject has history of cardiovascular ischemia in previous 3 months or acute
             myocardial infarction or unstable angina

          -  History of psychiatric disorder or cognitive impairment that would interfere with
             participation in the study

          -  History of alcoholism

          -  Contraindication against niacin and/or laropiprant

          -  Subject has participated in an investigational study within 30 days prior to study
             initiation

          -  Fasting triglycerides &gt;400 mg/dl

          -  Life-threatening disease (e.g. cancer)

          -  Renal insufficiency (GFR ≤ 30 ml/min )

          -  Major hepatic impairment

          -  Known allergic reaction/intolerance against niacin and/or laropiprant

          -  Active peptic ulcer disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Parhofer, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik II, Klinikum der Universitaet Muenchen, Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik II, Klinikum der Universitaet Muenchen, Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>December 2, 2013</results_first_submitted>
  <results_first_submitted_qc>March 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2014</results_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Klaus Parhofer</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Niacin/ Laropiprant</title>
          <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Niacin/ Laropiprant</title>
          <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incremental Area Under the Plasma Triglyceride Curve Over 8 Hours Following a Standardized Oral Fat Tolerance Test</title>
        <description>Percent change of incremental AUC at 12 weeks compared to baseline.</description>
        <time_frame>baseline and 12 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin/ Laropiprant</title>
            <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Area Under the Plasma Triglyceride Curve Over 8 Hours Following a Standardized Oral Fat Tolerance Test</title>
          <description>Percent change of incremental AUC at 12 weeks compared to baseline.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL Cholesterol</title>
        <description>Percent change of HDL-cholesterol at 12 weeks compared to baseline.</description>
        <time_frame>baseline and 12 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin/ Laropiprant</title>
            <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
          </group>
        </group_list>
        <measure>
          <title>HDL Cholesterol</title>
          <description>Percent change of HDL-cholesterol at 12 weeks compared to baseline.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Triglycerides</title>
        <description>Percent change of fasting triglycerides at 12 weeks compared to baseline</description>
        <time_frame>baseline and 12 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin/ Laropiprant</title>
            <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Triglycerides</title>
          <description>Percent change of fasting triglycerides at 12 weeks compared to baseline</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>LDL-cholesterol</title>
        <description>Percent change of LDL-cholesterol at 12 weeks compared to baseline</description>
        <time_frame>baseline and 12 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin/ Laropiprant</title>
            <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-cholesterol</title>
          <description>Percent change of LDL-cholesterol at 12 weeks compared to baseline</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Niacin/ Laropiprant</title>
          <description>Niacin/ Laropiprant: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Klaus G. Parhofer</name_or_title>
      <organization>University Munich</organization>
      <phone>+49-89-7095-3010</phone>
      <email>klaus.parhofer@med.uni-muenchen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

